众生药业：控股子公司收到RAY1225注射液新增适应症的药物临床试验批准通知书

Core Viewpoint - The announcement indicates that the innovative peptide drug RAY1225 injection, developed by the subsidiary of the company, has received approval from the National Medical Products Administration for a new indication to treat "metabolism-related fatty liver disease" [1] Group 1 - The drug RAY1225 injection is classified as a first-class innovative peptide medication [1] - The approval includes a clinical trial for the new indication, which signifies a potential expansion of the drug's therapeutic applications [1] - The company has received the "Drug Clinical Trial Approval Notice" confirming the initiation of clinical trials for the new indication [1]